

# The Journal of UROLOGY®

FOUNDED IN 1917 BY HUGH HAMPTON YOUNG

Official Journal of the American Urological Association, Inc.

## CONTENTS

### CLINICAL UROLOGY

#### Review Article

- Nonoperative Management of Benign Prostatic Hyperplasia. *H. Lepor* ..... 1283

#### Original Articles

- Selective Use of Excretory Urography in Women With Acute Pyelonephritis. *T. Sandberg, E. Stokland, I. Brolin, G. Lidin-Janson and C. Svanborg Edén* (Editorial Comments by H. M. Pollack and B. B. Garber) ..... 1290
- Elective Cholecystectomy During Major Urological Surgery. *T. A. Rozanski, V. J. Kiesling, Jr., J. A. Vaccaro and W. D. Belville* ..... 1295
- Impact of Endourology on Diagnosis and Management of Upper Urinary Tract Urothelial Cancer. *M. L. Blute, J. W. Segura, D. E. Patterson, R. C. Benson, Jr. and H. Zincke* (Editorial Comments by M. J. Droller and M. S. Soloway) ..... 1298
- Cardiovascular Evaluation Before Circulatory Arrest for Removal of Vena Caval Extension of Renal Carcinoma. *J. A. Belis, W. E. Pae, Jr., T. J. Rohner, Jr., J. L. Myers, B. L. Thiele, G. S. Wickey and D. E. Martin* (Editorial Comments by L. M. Zinman, J. A. Libertino, D. M. Shahian, F. F. Marshall and B. A. Reitz) ..... 1302
- Deoxyribonucleic Acid Content and Medroxyprogesterone Acetate Treatment in Metastatic Renal Cell Carcinoma. *B. Ljungberg, R. Tomić and G. Roos* ..... 1308
- Carcinoma of Renal Pelvis and Ureter Following Bladder Carcinoma. Frequency, Risk Factors and Clinicopathological Findings. *J. Oldbring, I. Glifberg, P. Mikulowski and S. Hellsten* ..... 1311
- Semirigid Ureteroscopy: New Genre. *S. P. Dretler and G. Cho* ..... 1314
- Endoureteropyelotomy: Percutaneous Treatment of Ureteropelvic Junction Obstruction. *P. J. Van Cangh, J. L. Jorion, F. X. Wese and R. J. Opsomer* (Editorial Comments by R. V. Clayman and A. D. Smith) .. 1317
- Continent Urinary Diversion. *D. G. Skinner, G. Lieskovsky and S. Boyd* (Editorial Comments by R. G. Rowland, A. I. Sagalowsky and W. F. Whitmore, Jr.) ..... 1323
- Malacoplakia: 25-Year Experience With Review of Literature. *J. P. Long, Jr. and A. F. Althausen* ..... 1328
- Flow Cytometry as Predictor of Response and Progression in Patients With Superficial Bladder Cancer Treated With Bacillus Calmette-Guerin. *P. R. Bretton, H. W. Herr, M. Kimmel, W. R. Fair, W. F. Whitmore, Jr. and M. R. Melamed* (Editorial Comment by R. W. deVere White) ..... 1332
- Intravesical Mitomycin C Instillation as Prophylactic Treatment of Superficial Bladder Tumor. *H. H. Kim and C. Lee* (Editorial Comments by M. S. Soloway and T. H. Stanisis) ..... 1337
- Complications of Whole Bladder Dihematoporphyrin Ether Photodynamic Therapy. *J. I. Harty, M. Amin, T. J. Wieman, M. T. Tseng, D. Ackerman and W. Broghamer* ..... 1341
- Late Occurrence of Urinary Tract Damage in Patients Successfully Treated by Radiotherapy for Cervical Carcinoma. *J. Zoubek, E. J. McGuire, F. Noll and J. O. L. DeLancey* ..... 1347

Contents continued on page A6

Annual Meeting, American Urological Association, Inc., New Orleans, Louisiana, May 13-17, 1990

Topical Oxybutynin Chloride for Relaxation of Dysfunctional Bladders. <i>C. B. Brendler, L. C. Radebaugh and J. L. Mohler</i> .....	1350
Anatomy of Penile Venous Drainage in Potent and Impotent Men During Cavernosography. <i>A. M. Fuchs, C. M. Mehringer and J. Rajfer</i> .....	1353
Impotence Evaluated by Use of Prostaglandin E1. <i>T. I.-S. Hwang, C.-R. Yang, S.-J. Wang, C.-L. Chang, T.-S. Tzai, C.-H. Chang and H.-C. Wu</i> (Editorial Comment by M. Marberger) .....	1357
Effect of Yohimbine Hydrochloride on Erectile Impotence: Double-Blind Study. <i>J. G. Susset, C. D. Tessier, J. Wincze, S. Bansal, C. Malhotra and M. G. Schwacha</i> .....	1360
Safety of Intracavernous Injections Using Alpha-Blocking Agent. <i>J. Buvat, A. Lemaire, M. Buvat-Herbaut and G. Marcolin</i> .....	1364
Malignant Lymphoma of Testis: Histological and Immunohistological Study of 28 Cases. <i>N. Nonomura, K. Aozasa, T. Ueda, A. Okuyama, M. Matsuda, S. Hida, O. Yoshida, Y. Kobashi, N. Shima and H. Yamabe</i> .....	1368
Incidence and Clinical Significance of Subclinical Scrotal Varicoceles. <i>M. A. Yarborough, J. R. Burns and F. S. Keller</i> .....	1372
Acute Urinary Retention Associated With Prostatic Carcinoma. <i>J. W. Moul, R. Davis, J. A. Vaccaro, S. A. Sihelnik, W. D. Belville and D. G. McLeod</i> .....	1375
Role of Prostatic Specific Antigen as Tumor Marker in Men With Advanced Adenocarcinoma of Prostate. <i>T. J. Maatman</i> (Editorial Comment by P. H. Lange and M. Brawer) .....	1378
Candidal Antigenemia: Prognostic Determinant. <i>T. Suits, G. J. Wise and B. Walters</i> .....	1381

### Urologists At Work

New Technique of Using In Situ Appendix as Catheterizable Stoma in Continent Urinary Reservoirs. <i>M. M. Issa, J. E. Oesterling, D. A. Canning and R. D. Jeffs</i> .....	1385
Adjunctive Endourological Technique for Transurethral Resection in Patients With Urethral Stricture. <i>R. K. Chiou, W. M. O'Brien and K. P. O'Connor</i> (Editorial Comment by W. Brannan) .....	1388

### Urological Neurology and Urodynamics

Bladder Hypocompliance in Spinal Cord Injury Population. <i>R. H. Hackler, M. K. Hall and T. A. Zampieri</i> .....	1390
Urodynamic Studies in Patients Undergoing Bladder Replacement Surgery. <i>B. Lytton and D. F. Green</i> .....	1394

### Pediatric Articles

Bilateral Ureteral Triplication With Crossed Ectopic Fused Kidneys Associated With VACTERL Syndrome. <i>J. Golomb and R. M. Ehrlich</i> .....	1398
Retroiliac Ureter in Male Newborn With Multiple Genitourinary Anomalies: Case Report and Review of Literature. <i>D. H. Nguyen, N. Koleilat and R. Gonzalez</i> .....	1400
Bladder Compliance in Meningomyelocele Children. <i>G. M. Ghoniem, D. A. Bloom, E. J. McGuire and K. L. Stewart</i> (Editorial Comment by S. B. Bauer) .....	1404
Technical Challenge of Megameatus Intact Prepuce Hypospadias Variant: Pyramid Procedure. <i>J. W. Duckett and M. A. Keating</i> .....	1407
Incidence, Possible Causes and Followup of Idiopathic Prolonged Penile Erection in Newborn. <i>P. Merlob and P. M. Livne</i> (Editorial Comment by A. B. Belman) .....	1410
Infant Testicular Prosthesis. <i>J. S. Elder, M. A. Keating and J. W. Duckett</i> (Editorial Comment by A. B. Belman) .....	1413
Orchiopexy of High Undescended Testis by Division of Spermatic Vessels: Critical Review of 38 Selected Transections. <i>S. J. Kogan, B. Z. Houtman, E. F. Reda and S. B. Levitt</i> (Editorial Comment by H. McC. Snyder, III) .....	1416

### Case Reports

Acquired Intravesical Ureteral Diverticulum: Unusual Late Complication of Ureteroneocystostomy. <i>F. Aragona, P. Bassi, G. Passerini Glazel and F. Pagano</i> .....	1420
Treatment of Vesicouterine Fistula by Fulguration. <i>L. R. Molina, C. M. Lynne and V. A. Politano</i> .....	1422
Bladder Pheochromocytoma: Evaluation With Magnetic Resonance Imaging. <i>J. Heyman, Y. Cheung, V. Ghali and E. Leiter</i> .....	1424
Treatment of Persistent Penile Erection and Priapism Using Terbutaline. <i>T. R. Shantha, D. P. Finnerty and A. P. Rodriguez</i> .....	1427
Tuberculosis of Penis Presenting as Subcutaneous Nodule. <i>L. S. Baskin and S. Mee</i> .....	1430
Conservative Management of Seminal Vesicle Abscess. <i>M. J. Kennelly and J. E. Oesterling</i> .....	1432

### Letter to the Editor

Re: Dorsal Lumbotomy Incision in Pediatric Urological Surgery, by S. M. Orland, H. M. Snyder and J. W. Duckett. <i>J. M. Mallafre, R. Gutierrez del Pozo and J. A. Campos C.</i> .....	1434
--	------

## INVESTIGATIVE UROLOGY

This Month in Investigative Urology: Host Parasite Interaction in Pyelonephritis. <i>J. A. Roberts</i> .....	1436
Ureaplasma Urealyticum Upper Urinary Tract Infection: Persistence and Pathogenicity in Canine Model. <i>J. N. Krieger, E. S. Boatman and G. E. Kenny</i> .....	1437
Acetylcholine as Possible Neurotransmitter in Penile Erection. <i>C. Stief, F. Benard, R. Bosch, S. Aboseif, L. Nunes, T. F. Lue and E. A. Tanagho</i> .....	1444
Class I and Class II HLA Antigen Expression by Transitional Cell Carcinoma of Bladder: Correlation With T-Cell Infiltration and BCG Treatment. <i>G. F. Stefanini, E. Bercovich, V. Mazzeo, W. F. Grigioni, E. Emili, A. D'Errico, M. Lo Cigno, N. Tamagnini and M. Mazzetti</i> .....	1449
Suppression of Rat Urinary Bladder Carcinogenesis by Alpha-Difluoromethylornithine. <i>Y. Homma, T. Kakizoe, S. Samma and R. Oyasu</i> .....	1454
pH Analysis of Papaverine-Phentolamine and Prostaglandin E <sub>1</sub> for Pharmacologic Erection. <i>E. J. Seidmon and A. M. Samaha, Jr.</i> .....	1458
In Vivo Transfer of R-Plasmid in Urinary Tract Infection Model. <i>D. E. Neal, Jr., E. E. M. Moody, V. L. Thomas, R. Gander and H. M. Radwin</i> .....	1460
Effects of Anti-Lipid A Human Monoclonal Antibody on Lipopolysaccharide-Induced Toxicity to Kidney. <i>B. M. Tune, C.-Y. Hsu, M. M. Bieber and N. N. H. Teng</i> .....	1463
Immunoreponse of Tissue Infiltrating Lymphocytes in Bladder Tumors. <i>H. Tsujihashi, H. Matsuda, S. Uejima, T. Akiyama and T. Kurita</i> .....	1467
In Vitro Intravesical Instillation of Anticholinergic Antispasmodic and Calcium Blocking Agents (Rabbit Whole Bladder Model). <i>K. Kato, S. Kitada, A. Chun, A. J. Wein and R. M. Levin</i> .....	1471
Regeneration of Canine Urinary Bladder Mucosa After Complete Surgical Denudation. <i>K. I. Wishnow, D. E. Johnson, D. J. Grignon, D. M. Cromeens and A. G. Ayala</i> .....	1476
Prostatic Specific Antigen: Immunoreactivity in Urachal Remnants. <i>R. Golz and G. E. Schubert</i> .....	1480
Characterization and Localization of In Vivo Phospholipid Methylation in Hamster Testis. <i>P. N. Schlegel, W. W. Wright and T. S. K. Chang</i> .....	1483
Investigative Grammar .....	1488

## UROLOGICAL SURVEY

<b>Subject Index to Abstracts in Volume 141</b> .....	1490
Diagnostic Efficacy of Combination of Urine Cytology, Urine Analysis and History in Follow-Up of Bladder Carcinoma. <i>E. J. H. Meuleman and K. P. J. Delaere</i> .....	1498
Impact of Hydronephrosis on Renal Function in Patients Treated With Cisplatin-Based Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumors. <i>C. Barton, G. Duchesne, M. Williams, C. Fisher and A. Horwich</i> .....	1498
Results of Adjuvant Surgery in Patients With Stage III and IV Nonseminomatous Testicular Tumors After Cisplatin-Vinblastine-Bleomycin Chemotherapy. <i>W. A. H. Gelderman, H. Schraffordt Koops, D. Th. Sleijfer, J. W. Oosterhuis, J. N. H. Van Der Heide, N. H. Mulder, J. Marrink, H. W. A. De Bruyn and J. Oldhoff</i> .....	1498
Cisplatin-Based Combination Chemotherapy for Disseminated Germ Cell Tumors: Long-Term Follow-Up. <i>B. J. Roth, A. Greist, P. S. Kubilis, S. D. Williams and L. H. Einhorn</i> .....	1499
Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients With Good-Prognosis Germ Cell Tumors. <i>G. J. Bosl, N. L. Geller, D. Bajorin, S. P. Leitner, A. Yagoda, R. B. Golbey, H. Scher, N. J. Vogelzang, J. Auman, R. Carey, W. R. Fair, H. Herr, M. Morse, P. Sogani and W. Whitmore, Jr.</i> .....	1499
Surveillance for Stage I Non-Seminomatous Germ Cell Tumours of Testis: Optimal Protocol Has Not Yet Been Defined. <i>D. Raghavan, B. Colls, J. Levi, B. Fitzharris, M. H. N. Tattersall, C. Atkinson, R. Woods, G. Coorey, C. Farrell and R. Wines</i> .....	1500
Clinical Stage I Nonseminomatous and Mixed Germ Cell Tumors of Testis: Clinicopathologic Study of 93 Patients on Surveillance Protocol After Orchiectomy Alone. <i>C. H. Dunphy, A. G. Ayala, D. A. Swanson, J. Y. Ro and C. Logothetis</i> .....	1500
Stage I Nonseminomatous Germ Cell Testicular Tumor: Prediction of Metastatic Potential by Primary Histopathology. <i>C. Y. Fung, L. A. Kalish, G. L. Brodsky, J. P. Richie and M. B. Garnick</i> .....	1501
Renal Acidification Defects in Medullary Sponge Kidney. <i>P. J. Osther, A. B. Hansen and H. F. Røhl</i> .....	1501
Improvement of Renal Function in Azotaemic Hypertensive Patients After Surgical Revascularization. <i>C. A. Mestres, J. M. Campistol, S. Ninot, A. Botey, C. Abad, M. Guerola, A. Cases, L. Revert and J. Mulet</i> ..	1501
Management of Children With Hypertension From Reflux or Obstructive Nephropathy. <i>V. Braren, J. C. West, Jr., R. C. Boerth and C. M. Harmon</i> .....	1502
New Approach to Treatment of Polycystic Kidneys. <i>D. Frang, I. Czvalinga and L. Polyák</i> .....	1502
Renal Pathology in von Hippel-Lindau Disease. <i>D. Solomon and A. Schwartz</i> .....	1502
Renewed Role of Nuclear Medicine in Renovascular Hypertension. <i>M. D. Blaufox and L. M. Freeman</i> .....	1502
Cadaveric Renal Transplantation in Cyclosporine and OKT3 Eras. <i>R. J. Stratta, A. M. D'Alessandro, R. M. Hoffmann, H. W. Sollinger, M. Kalayoglu, D. F. Lorentzen, J. D. Pirsch and F. O. Belzer</i> .....	1503
Effectiveness of Second Course of OKT3 Monoclonal Anti-T Cell Antibody for Treatment of Renal Allograft Rejection. <i>D. J. Norman, C. F. Shield, III, K. R. Henell, J. Kimball, J. M. Barry, W. M. Bennett and M. Leone</i> .....	1503

Early Function as Principal Correlate of Graft Survival. Multivariate Analysis of 200 Cadaveric Renal Transplants Treated With Protocol Incorporating Antilymphocyte Globulin and Cyclosporine. <i>P. F. Halloran, M. A. Aprile, V. Farewell, D. Ludwin, E. K. Smith, S. Y. Tsai, R. A. Bear, E. H. Cole, S. S. Fenton and D. C. Cattran</i> .....	1514
Efficacy of Ganciclovir in Liver and Kidney Transplant Recipients With Severe Cytomegalovirus Infection. <i>C. V. Paya, P. E. Hermans, T. F. Smith, J. Rakela, R. H. Wiesner, R. A. F. Krom, V. E. Torres, S. Sterioff and C. J. Wilkowske</i> .....	1515
Renal Artery Stenosis After Renal Transplantation. <i>M. Lacombe</i> .....	1515
Recurrent Pulmonary Oedema in Hypertension Due to Bilateral Renal Artery Stenosis: Treatment by Angioplasty or Surgical Revascularisation. <i>T. G. Pickering, L. Herman, R. B. Devereux, J. E. Sotelo, G. D. James, T. A. Sos, M. F. Silane and J. H. Laragh</i> .....	1516
Aortorenal Arterial Autografts: Last Two Decades. <i>R. J. Stoney and P. A. Olofsson</i> .....	1517
Simultaneous Aortic Reconstruction and Bilateral Renal Revascularization: Is This Safe and Effective Procedure? <i>C. S. O'Mara, M. D. Maples, T. L. Kilgore, Jr., M. H. McMullan, H. B. Tyler, G. H. Mundinger, Jr. and R. E. Kennedy</i> .....	1517
Results of Renal Artery Balloon Angioplasty Limit its Indications. <i>H. G. Beebe, K. Chesebro, F. Merchant and W. Bush</i> .....	1518
Surgical Renal Artery Reconstruction After Percutaneous Transluminal Angioplasty. <i>R. L. McCann, R. R. Bollinger and G. E. Newman</i> .....	1519
Urinary-Bladder Management After Total Joint-Replacement Surgery. <i>J. D. Michelson, P. A. Lotke and M. E. Steinberg</i> .....	1519
Treatment of Urinary Complications After Total Joint Replacement in Elderly Females. <i>V. L. Carpiello, T. R. Malloy, M. Cendron, R. Booth and H. G. Altman</i> .....	1519
Can Transabdominal Ultrasound Estimation of Postvoiding Residual (PVR) Replace Catheterization. <i>C. G. Roehrborn and P. C. Peters</i> .....	15110
Residual Urine Volumes in Patients With Spinal Cord Injury: Measurement With Portable Ultrasound Instrument. <i>D. D. Cardenas, E. Kelly, J. N. Krieger and W. H. Chapman</i> .....	15110
Effect of Pelvic Floor Exercises in Treatment of Genuine Urinary Stress Incontinence in Women at Two Hospitals. <i>S. M. Henalla, P. Kirwan, C. M. Castleden, C. J. Hutchins and A. J. Breeson</i> .....	15111
Pelvic-Floor Musculature Exercises in Treatment of Anatomical Urinary Stress Incontinence. <i>D. C. H. Tchou, C. Adams, R. E. Varner and B. Denton</i> .....	15111
Clinical and Urodynamic Effects of Anterior Vaginal Repair and Burch Colposuspension. <i>J. M. van Geelen, A. G. M. Theeuwes, T. K. A. B. Eskes and C. B. Martin, Jr.</i> .....	15112
Estrogens and Phenylpropanolamine in Combination for Stress Urinary Incontinence in Postmenopausal Women. <i>A.-C. Kinn and M. Lindskog</i> .....	15112
Norfeneprine in Treatment of Female Stress Incontinence: Double-Blind Controlled Trial. <i>G. Lose, P. Rix, E. Diernoës and N. Alexander</i> .....	15113
Urinary Incontinence During Sexual Intercourse: Common, but Rarely Volunteered, Symptom. <i>P. Hilton</i> .....	15113
Long-Term Follow-Up of Selective Sacral Neurectomy. <i>M. G. Lucas, D. G. Thomas, S. Clarke and D. M. C. Forster</i> .....	15114
Acupuncture in Treatment of Bladder Instability. <i>T. Philp, P. J. R. Shah and P. H. L. Worth</i> .....	15114
Role of Urethral Reconstruction and Artificial Sphincter in Complicated Salvage Radical Prostatectomy. <i>S. D. Boyd</i> .....	15115
Radical Pelvic Surgery With Preservation of Sexual Function. <i>P. C. Walsh and P. N. Schlegel</i> .....	15115
Pelvic Fracture and Injury to Lower Urinary Tract. <i>J. P. Spirnak</i> .....	15116
Save Prepuce. Painless Separation of Preputial Adhesions in Outpatient Clinic. <i>G. A. MacKinlay</i> .....	15117
Do You Favor Routine Neonatal Circumcision? Yes. <i>T. E. Wiswell</i> .....	15117
Fracture of Penis—Review With Case Report. <i>J. T. K. Tiong, A. Taylor, E. England and R. Hirsch</i> .....	15117
Other Arthritides: Roentgenologic Features of Osteoarthritis, Erosive Osteoarthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Reiter's Disease, Multicentric Reticulohistiocytosis, and Progressive Systemic Sclerosis. <i>R. H. Gold, L. W. Bassett and L. L. Seeger</i> .....	15118
Demonstration of Rectovesical Fistula on Technetium-99m MDP Bone Image. <i>K. Higashi, M. Ohguchi, T. Okimura, T. Miyamura and I. Yamamoto</i> .....	15118

## Volume Index and Contents

Index, Volume 141 .....	15119
Table of Contents, Volume 141 .....	iii

### PROPRIETARY NAMES

Many of the words appearing in the JOURNAL OF UROLOGY are proprietary names even though no reference to this fact is made in the text. The appearance of any name without designation as proprietary is, therefore, not to be regarded as a representation by the editorial committee or publisher that it is not the subject of proprietary rights.

# ACETYLCHOLINE AS A POSSIBLE NEUROTRANSMITTER IN PENILE ERECTION

CHRISTIAN STIEF, FRANCOIS BENARD, RUUD BOSCH, SHERIF ABOSEIF, LORA NUNES,  
TOM F. LUE\* AND EMIL A. TANAGHO

*From the Department of Urology, University of California School of Medicine, San Francisco, California*

## ABSTRACT

We investigated the erectile response to intracavernous injection of increasing doses of acetylcholine (0.5 to 500  $\mu$ g.) in 10 monkeys. To differentiate between nicotinic (ganglionic) and muscarinic (parasympathetic postganglionic) effects, acetylcholine was likewise administered after 1.6 mg. trimethaphan camsylate and 0.1 mg. atropine, alone or sequentially. Erections were induced by cavernous nerve stimulation before and after atropine.

Acetylcholine induced a dose-dependent, triphasic erectile response: a first tumescence phase followed by contraction and a subsequent second phase of tumescence. Atropine reduced but did not abolish the erectile response to acetylcholine: attainment of maximal intracavernous pressure after neurostimulation was both delayed and reduced (mean 25 cm. H<sub>2</sub>O). Only after combined nicotinic and muscarinic blockade was the erectile response to acetylcholine completely abolished. Histologic staining for acetylcholinesterase in five additional monkeys that had not received acetylcholine showed dense staining within the cavernous erectile tissue and around the cavernous arteries.

Our data suggest that acetylcholine is a possible neurotransmitter for penile erection in monkeys. (*J. Urol.*, 141: 1444-1448, 1989)

Since the report of Eckhardt in 1863 that galvanic stimulation of pelvic parasympathetic nerves induces penile erection in the dog,<sup>1</sup> many studies have confirmed these findings in different species.<sup>2-7</sup> Based on the classic theory of autonomic neurotransmission, the muscarinic neurotransmitter was believed to be acetylcholine (ACh).<sup>8</sup> However, penile erection has been shown to be atropine-resistant,<sup>9,10</sup> and organ bath studies of the effect of ACh on cavernous smooth muscle have been inconclusive. In vitro, all possible responses to ACh have been observed: no effect;<sup>11,12</sup> inconsistent effects;<sup>13</sup> and both contraction<sup>14</sup> and relaxation<sup>15,16</sup> of the cavernous smooth muscle. Our aim was to examine in vivo a possible role of ACh as a postganglionic parasympathetic neurotransmitter for penile erection.

## MATERIALS AND METHODS

Ten pigtail monkeys, weighing 4.3 to 10.5 kg., were used. After adequate anesthesia with ketamine (30 mg./kg. body-weight i.m.), the monkeys were placed in the supine position. Under sterile conditions, one 21-gauge scalp-vein needle was placed in each distal right and left cavernous body. One needle was connected to a Statham transducer (model P23 BC) for intracavernous pressure recording (Grass Polygraph; model 7); the other served for intracavernous injection or perfusion. Penile tumescence was visually monitored by at least two investigators and recorded. The flow through the cavernous arteries was measured in four monkeys (No. 7-10) by duplex ultrasound.<sup>17</sup> Pulse and blood pressure were monitored closely with the aid of a Doppler probe (Parks Medical Electronics) on the radial artery and a pediatric blood pressure cuff (fig. 1).

*Intracavernous injection of ACh.* All monkeys received doses of 0.5, 1 ( $5 \times 10^{-9}$  mol.), 10, 100 and 500  $\mu$ g. ACh (Miocholine, Cooper Vision, Puerto Rico) by intracavernous injection. The effects of each dose were allowed to subside and a 10 to 15

minute waiting period intervened before the next injection. To verify reproducibility, all injections were given twice.

*Intracavernous injection of ACh after muscarinic blockade.* The above injection protocol was followed after intracavernous injection of 0.1 mg. atropine ( $1.4 \times 10^{-7}$  mol.) (Elkins-Sim Inc., Cherry Hill, N.Y.). This dosage was chosen after 0.01 mg. intracavernously proved to be sufficient for complete muscarinic blockade in dogs (unpublished data). Although the size of the cavernous bodies in monkeys and dogs is comparable, a ten-fold increase (0.1 mg.) was selected to ensure complete local muscarinic blockade.

*Erections induced by neurostimulation before and after atropine.* In monkeys 1-6, cuff electrodes were placed around the cavernous nerve as previously described.<sup>18</sup> After three erections had been induced by neurostimulation (20 Hz, six to eight V, stimulation time = one minute), 0.1 mg. atropine was injected intracavernously and neurostimulation was repeated five times with an eight-minute interval between each stimulation.

*Intracavernous injection of ACh after nicotinic blockade.* To investigate the effect of ACh after nicotinic blockade, the six monkeys with implanted electrodes were given an intracavernous injection of 1.6 mg. trimethaphan camsylate (Roche Laboratories, Nutley, N.J.), the lowest dosage shown to block neurostimulation-induced erections in all monkeys. The drug's intrinsic activity resulted in penile tumescence with venous occlusion for 180 to 290 seconds (mean 235 seconds). However, during this period and for the next 180 to 200 seconds, the erectile response to neurostimulation was completely abolished. Acetylcholine (0.5 mg.) was injected intracavernously after trimethaphan camsylate's intrinsic activity had subsided (by direct vasodilation and smooth muscle relaxation) but during maintenance of nicotinic blockade.

Injection of trimethaphan camsylate and ACh was repeated after 0.1 mg. atropine.

*The effect of ACh on the cavernous outflow.* In five monkeys, a flow probe was placed around the pudendal artery and the aorta was dissected for intermittent clamping with a Satinsky clamp. With the aorta clamped and the intracavernous pressure at baseline (mean 11 cm. H<sub>2</sub>O), the penis was perfused with

Accepted for publication December 15, 1988.

\* Requests for reprints: Dept. of Urology, University of California School of Medicine, San Francisco CA 94143.

Supported by a grant from Deutsche Forschungsgemeinschaft.




FIG. 1. Erection was induced in monkeys by cavernous nerve stimulation or intracavernous injection. Arterial response was measured by Duplex ultrasound or by flow probe placed around pudendal artery, or both. Intracavernous pressure response was recorded via needle inserted in cavernous body.

saline (37C) at increasing rates (3.8, 7.6, 15.3 and 26.6 ml./min.) before and after 0.5 mg. ACh intracavernously. When the perfusion had continued for 60 seconds or the intracavernous pressure surpassed 200 cm. H<sub>2</sub>O, it was stopped. After intervals of 90, 60 and 60 seconds the penis was re-perfused. The clamp on the aorta was then released.

**Histologic staining for acetylcholinesterase.** In five monkeys in which no neurotransmitter studies had been performed (i.e. animals to be sacrificed by other departments at our institution), the aorta was clamped and the distal aorta was perfused with two liters of saline to wash the red blood cells from the penile tissue. The penis was then immediately frozen and stained for acetylcholinesterase (AChE).<sup>19</sup>

## RESULTS

**Intracavernous injection of ACh.** Intracavernous injection of ACh induced a dose-dependent increase in penile tumescence, intracavernous pressure, and flow through the internal pudendal artery (fig. 2). The lowest dosage that induced penile tumescence was 0.5  $\mu$ g. in three monkeys, one  $\mu$ g. in six, and 10  $\mu$ g. in one. The first observable change was an increase in arterial flow, followed by penile tumescence, and then, after some seconds, by an increase in intracavernous pressure. The duration of tumescence increased with increasing dosages: from a mean of nine seconds (zero to 14 seconds) after 0.5  $\mu$ g. to a mean of 82 seconds (60 to 96) after 500  $\mu$ g. ACh.

A characteristic tri-phasic response was seen in seven monkeys with dosages up to 100  $\mu$ g. and two monkeys up to 500  $\mu$ g. Acetylcholine first induced penile tumescence and a rise in intracavernous pressure. This was followed by penile contraction and a plateau in intracavernous pressure at a level above baseline (fig. 2). During penile contraction, the arterial flow within the cavernous artery was markedly greater than in the flaccid state. This contraction was followed by another increase in tumescence and intracavernous pressure, both less dramatic than those in the first phase (table 1).




FIG. 2. Erectile responses to intracavernous injection of ACh at different doses.

A multi-peaked, wave-shaped intracavernous pressure response was seen after 100  $\mu$ g. in three monkeys and after 500  $\mu$ g. in four (fig. 2). In the majority, 0.5  $\mu$ g. ACh caused the systemic blood pressure to fall below 40 mm. Hg for about 20 to 40 seconds.

**Intracavernous injection of ACh after muscarinic blockade by atropine.** Intracavernous injection of 0.1 mg. atropine was not followed by changes in heart rate or systemic blood pressure. It induced an increase in the arterial flow of brief duration (five to 10 seconds) and slight tumescence lasting 10 to 25 seconds. The subsequent response to ACh remained dose-dependent: 0.5 and one  $\mu$ g. did not result in tumescence, but only in penile contraction with a subsequent intracavernous pressure increase (table 1). Compared with the effect induced by ACh alone, the response to ACh after atropine injection was markedly different: the duration of tumescence and the increase in intracavernous pressure and arterial flow were less; the contraction phase was more pronounced (high intracavernous pressure) and more prolonged; no second tumescence phase occurred. In the monkeys with wave-shaped erectile responses to 100 and 500  $\mu$ g. ACh, the same doses after atropine induced a continuous, sustained erectile response.

**Erection induced by neurostimulation before and after atropine.** In all six monkeys with electrodes around the cavernous nerve, electrical stimulation induced a reproducible full erection. After 0.1 mg. atropine, the first neurostimulation produced the same full erection as before. In the subsequent neurostimulated erections, the phase until attainment of maximal intracavernous pressure was prolonged by 10 to 34% (mean 28%; a mean delay of four seconds;  $p < 0.001$  [Student's *t* test]) and

TABLE 1. Erectile response to acetylcholine before and after atropine

ACh ( $\mu$ g.)	First Tumescence		Contraction		Second Tumescence	
	Duration (min.)	Pressure* (cm. H <sub>2</sub> O)	Duration (min.)	Pressure (cm. H <sub>2</sub> O)	Duration (min.)	Pressure (cm. H <sub>2</sub> O)
0.5	15	35†	90	60	60	32
1	24	40	120	60	60	40
10	32	65	120	60	70	40
100	54	105	150	60	90	25
500	84	120	180	75	90	25
After 0.1 mg. atropine						
0.5	-	-	40	60	-	-
1	-	-	62	60	-	-
10	14	42	165	90	-	-
100	22	60	210	100	-	-
500	30	75	260	100	-	-

\* Intracavernous pressure.

† Numbers represent mean values for all monkeys that responded (3 to 0.5  $\mu$ g., 6 to 1.0  $\mu$ g., 7 to 10  $\mu$ g., and all 10 to 100 and 500  $\mu$ g.).

the full erection pressure was decreased by 12 to 20% (mean 16% or 25 cm. H<sub>2</sub>O;  $p < 0.05$ ). The detumescence phase was unchanged. The immediate, strong increase in flow within the internal pudendal artery at cavernous nerve stimulation was decreased by a mean of 29%.

*Intracavernous injection of ACh after nicotinic blockade by trimethaphan camsylate.* Intracavernous injection of trimethaphan camsylate was followed by a mean reduction in systemic blood pressure of 12 cm. H<sub>2</sub>O for two to three minutes. After nicotinic blockade, intracavernous injection of 0.5 mg. ACh induced a similar erection to the one before trimethaphan camsylate, but attainment of maximal intracavernous pressure was delayed by a mean of nine seconds.

The injection of 0.5 mg. ACh after 0.1 mg. atropine and nicotinic blockade induced slight penile tumescence in one of the six monkeys, but no tumescence or increase in intracavernous pressure in five.

*The effect of ACh on the cavernous outflow.* With the aorta clamped, saline perfusion after ACh injection resulted in a perfusion-dependent plateau in intracavernous pressure without penile tumescence. Immediately after injection of 0.5 mg. ACh, perfusion rates of 3.8 ml./min. and higher induced full penile erection (intracavernous pressure > 200 cm. H<sub>2</sub>O). Reperfusion after 90 seconds produced the same result. However, with the third perfusion, flow rates up to 26.6 ml./min. did not induce any tumescence, although, at the fourth perfusion, flow rates  $\geq 15.3$  ml./min. again induced full erection (fig. 3). Thus, this perfusion study shows that intracavernous injection of ACh induced cavernous smooth muscle relaxation and subsequent cavernous outflow occlusion during the first two perfusions, but no cavernous occlusion (or smooth muscle relaxation) during the third. With the fourth perfusion, cavernous occlusion was again demonstrated, although it was not as pronounced as immediately after ACh injection (probably owing to a lesser degree of smooth muscle relaxation). Thus, the perfusion study confirmed the above-described findings of a triphasic erectile response to intracavernous ACh.

*Histologic findings.* In the histologic sections from the five monkeys, dense staining for acetylcholinesterase was seen around the cavernous artery, within nerves near the cavernous artery, and within the cavernous erectile tissues. No staining was found in the tunica albuginea (fig. 4).

#### DISCUSSION

Intracavernous injection of ACh in the monkey induced a triphasic, dose-dependent erectile response: a first phase of penile tumescence and rigidity; a phase of penile contraction; and a second phase of penile tumescence, not as pronounced as the first. This triphasic reaction with contraction between two phases of tumescence may be explained by an immediate or reflexogenic release of noradrenaline from noradrenergic nerves.<sup>20</sup> Carbachol has been reported to induce a similar effect in vitro: cavernous smooth muscle relaxation followed by con-




FIG. 3. With aorta clamped and 500  $\mu$ g. ACh injected intracavernously, saline perfusion induced venous occlusion at minutes 0 and 1 (first tumescence phase). At minute 3, no venous occlusion could be induced by perfusion rates below 26.6 ml./min. (contraction phase). Then, at minutes 5 and 7, venous occlusion was produced by flow rates of 15.3 ml./min. and greater.

traction.<sup>15</sup> After the effect of noradrenaline on its receptors has subsided, the second phase of tumescence could be explained by the ongoing effect of ACh on the cavernous smooth muscles in combination with the ongoing increase in arterial flow. The initial small dip in the intracavernous pressure at the beginning of this second phase of tumescence (fig. 2) can easily be explained by the elongation of the penis at this time.

Intracavernous ACh provoked an immediate, strong increase in arterial flow, which subsided somewhat but remained at moderately increased levels during the three phases. These pressure and flow effects were not due solely to a muscarinic cholinergic effect because they could not be completely blocked by atropine. Only after the additional intracavernous injection of a nicotinic blocker did ACh induce no erectile response. These observations correspond to the findings of Adaikan and




FIG. 4. Dense acetylcholinesterase-positive areas (dark spots) were found A, around cavernous arteries and B, within cavernous erectile tissue. (Magnification  $\times 200$  and  $\times 400$  for A and B, respectively.)

coworkers,<sup>13</sup> who demonstrated muscarinic and nicotinic cholinergic receptors in human cavernous tissue. This overlapping of muscarinic and nicotinic effects after the intracavernous injection of ACh, together with an increasing effect on the systemic blood pressure with doses of 0.1 and 0.5 mg., can explain the two (or more) wave-shaped erectile responses to high doses of ACh in seven monkeys.

Atropine modulated but did not abolish the erectile response to neurostimulation. The reduction of the immediate increase in arterial flow led to a prolongation of the tumescence phase. This and the decreased intracavernous pressure were supported as signs of incomplete cavernous relaxation by the staining of AChE around the cavernous artery and within the cavernous smooth muscles on histologic examination.

Our findings of the erectile response to intracavernous injection of ACh are in agreement with other *in vivo* studies: partial or full erections have been described after ACh in the rabbit<sup>21</sup> and dog;<sup>22</sup> atropine has been shown to reduce significantly the erectile response to pelvic and hypogastric nerve stimulation in the dog,<sup>4</sup> cat<sup>23</sup> and rabbit;<sup>21</sup> AChE-containing nerve fibers have been found in the cavernous tissue and around the cavernous artery in man and different animal species.<sup>11, 12, 24-26</sup>

At variance, Henderson et al. observed no erectile response after intraaortic injection of ACh.<sup>3</sup> This lack of effect may be due to the immediate inactivation of ACh by the AChE in the blood, to the pronounced lowering of the systemic blood pressure after high doses of ACh, or to the fact that the pressure in the glans instead of in the cavernous bodies was recorded. The ability of atropine to antagonize penile erection in man could not be proven in two studies.<sup>9, 10</sup> However, intracavernous pressure was not monitored by invasive means and a 15 or 20% lowering of the maximal pressure could have been easily missed.

Results of *in vitro* studies of the effect of ACh on the cavernous smooth muscle have been contradictory, showing a range of results: no effect;<sup>11, 12</sup> inconsistent effects;<sup>13</sup> contraction;<sup>14</sup> and relaxation.<sup>15, 16</sup> These contradictory findings may have several causes. To prove a relaxing effect, the cavernous smooth muscle must first be contracted by electrical or pharmacologic means. In the studies in which the smooth muscles were contracted by norepinephrine before ACh was given, a relaxing effect could be shown. Secondly, the human cavernous smooth muscle, like the monkey's, will probably react to intracavernous injection of ACh in a triphasic manner, but the dog responds with a single phase of tumescence and rigidity (unpublished data). Thirdly, the action of ACh may be dependent on an intact cavernous endothelium (Goldstein, I.: personal communication). In the studies in which no effect was observed, the cavernous endothelium may have been damaged during preparation of the tissue.

Our study showed that intracavernous injection of ACh in

the monkey induces a dose-dependent erectile response by increasing the arterial flow, relaxing the cavernous smooth muscles, and occluding the cavernous outflow. These *in vivo* results, together with the histologic findings of AChE-positive fibers around the cavernous artery and within the cavernous erectile tissue, suggest that ACh may be a neurotransmitter for penile erection. The fact that atropine could only diminish, but not abolish, the erectile response to neurostimulation suggests the presence of additional postganglionic parasympathetic neurotransmitters for erection. There is strong evidence that vasoactive intestinal polypeptide (VIP) may be one of these.<sup>27-30</sup> We have observed that the combination of atropine and anti-VIP likewise only reduces the erectile response to neurostimulation (unpublished data), and therefore further studies are needed to uncover additional neurotransmitters involved in penile erection.

#### REFERENCES

- Eckhardt, C.: Untersuchungen über die Erektion des Hundes. *Beitr. Anat. Physiol.*, **3**: 123, 1863.
- Langley, J. N. and Anderson, H. K.: The innervation of the pelvic and adjoining viscera III. The external generative organs. *J. Physiol.*, **19**: 85, 1895-96.
- Henderson, V. E. and Roepke, M. H.: On the mechanism of erection. *Am. J. Physiol.*, **106**: 441, 1933.
- Dorr, L. D., Brody, M. J.: Hemodynamic mechanisms of erection in the canine penis. *Am. J. Physiol.*, **213**: 1526, 1967.
- Siroky, M. B. and Krane, R. J.: Neurophysiology of erection In: *Male Sexual Dysfunction*. Edited by Krane, R. J., Siroky, M. B. and Goldstein, I. Boston: Little Brown Co, 1983.
- Lue, T. J., Takamura, T., Schmidt, R. A., Palubinskas, A. J. and Tanagho, E. A.: Hemodynamics of erection in the monkey. *J. Urol.*, **130**: 1237, 1983.
- Carati, C. J., Creed, K. E. and Keogh, E. J.: Autonomic control of penile erection in the dog. *J. Physiol.*, **384**: 525, 1987.
- Mayer, S. E.: Neurohumoral transmission and the autonomic nervous system. In: *The Pharmacological Basis of Therapeutics*. Edited by A. Goodman Gilman, A. Goodman and L. S. Gilman. New York: Macmillan, vol. 7, chapt. 4, pp. 56-90, 1985.
- Wagner, G. and Brindley, G. S.: The effect of atropine and alpha and beta blockers on human penile erection: a controlled pilot study. In: *Vasculogenic Impotence*. Edited by A. W. Zorgniotti and G. Rossi. Springfield: Charles C. Thomas, p. 77, 1978.
- Brindley, G. S.: Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. *Br. J. Pharmacol.*, **87**: 495, 1986.
- McConnell, J., Benson, G. S. and Wood, J.: Autonomic innervation of the mammalian penis: A histochemical and physiological study. *J. Neural Transm.*, **45**: 227, 1979.
- Benson, G. S., McConnell, J., Lipshultz, L. I., Corriere, J. N., Jr. and Wood, J.: Neuromorphology and neuropharmacology of the human penis: an *in vitro* study. *J. Clin. Invest.*, **65**: 506, 1980.



13. Adaikan, P. G., Karim, S. M. M., Kottegoda, S. R. and Ratnam, S. S.: Cholinoreceptors in the corpus cavernosum muscle of the human penis. *J. Autonom. Pharmacol.*, **3**: 107, 1983.
14. Klinge, E. and Sjöstrand, N. O.: Comparative study of some isolated mammalian smooth muscle effectors of penile erection. *Acta Physiol. Scand.*, **100**: 354, 1977.
15. Carati, C. J., Goldie, R. G., Warton, A., Henry, P. J. and Keogh, E. J.: Pharmacology of the erectile tissue of the canine penis. *Pharm. Res. Commun.*, **17**: 951, 1985.
16. Hedlund, H. and Andersson, K.-E.: Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. *J. Urol.*, **134**: 1245, 1985.
17. Lue, T. F., Hricak, H., Marich, K. W. and Tanagho, E. A.: Vasculogenic impotence evaluated by high resolution ultrasonography and pulsed Doppler spectrum analysis. *Radiology*, **155**: 777, 1987.
18. Lue, T. F.: The mechanism of penile erection in the monkey. *Semin. Urol.*, **4**: 217, 1986.
19. Goto, S., Ikeda, K. and Toyohara, T.: An improved staining technique for acetylcholinesterase activity using rubeanic acid in the diagnosis of Hirschsprung's disease. *Jap. J. Surg.*, **14**: 135, 1984.
20. Starke K.: *Reviews of Physiology, Biochemistry and Pharmacology*. Springer Verlag, Berlin, 1977.
21. Sjöstrand, N. O., Klinge, E.: Principal mechanisms controlling penile retraction and protrusion in rabbits. *Acta Physiol. Scand.*, **106**: 199, 1979.
22. Valji, K. and Bookstein, J. J.: The veno-occlusive mechanism of the canine corpus cavernosum: angiographic and pharmacologic studies. *J. Urol.*, **138**: 1467, 1987.
23. Domer, F. R., Wessler, G., Brown, R. L. and Charles, H. C.: Involvement of the sympathetic nervous system in the urinary bladder internal sphincter and in penile erection in the anesthetized cat. *Invest. Urol.*, **15**: 404, 1978.
24. Klinge, E. and Penttilä, O.: Distribution of noradrenaline and acetylcholinesterase in bull and rabbit penile erectile tissue. *Ann. Med. Exp. Fenn.*, **47**: 17, 1969.
25. Shirai, M., Sasaki, K. and Rikimaru, A.: Histochemical investigation on the distribution of adrenergic and cholinergic nerves in human penis. *Tohoku J. Exp. Med.*, **107**: 403, 1972.
26. Gu, J., Polak, J. M., Probert, L., Islam, K. N., Marangos, P. J., Mina, S., Adrian, T. E., McGregor, G. P., O'Shaughnessy, D. J. and Bloom, S. R.: Peptidergic innervation of the human male genital tract. *J. Urol.*, **130**: 386, 1983.
27. Polak, J. M., Gu, J., Mina S. and Bloom, S. R.: VIPergic nerves in the penis. *Lancet*, **2**: 217, 1981.
28. Andersson, P.-O., Bloom, S. R. and Mellander, S.: Haemodynamics of pelvic nerve induced penile erection in the dog: possible mediation by vasoactive intestinal polypeptide. *J. Physiol.*, **350**: 209, 1984.
29. Juenemann, K.-P., Lue, T. F., Luo, J.-A., Jadallah, S. A., Nunes, L. L. and Tanagho, E. A.: The role of vasoactive intestinal polypeptide as a neurotransmitter in canine penile erection: a combined in vivo and immunohistochemical study. *J. Urol.*, **138**: 871, 1987.
30. Lincoln, J., Crowe, R., Blacklay, P. F., Pryor, J. P., Lumley, J. S. P. and Burnstock, G.: Changes in the VIPergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic impotent males. *J. Urol.*, **137**: 1053, 1987.